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Abstract (Word Count 250) 
Background: Pseudomonas aeruginosa is the most common bacterial pathogen in cystic fibrosis 
(CF) patients.  Current infection control guidelines aim to prevent transmission via contact and 
respiratory droplet routes and do not consider the possibility of airborne transmission. We 
hypothesized that with coughing, CF subjects produce viable, respirable bacterial aerosols. 
Methods: Cross-sectional study of 15 children and 13 adults with CF, 26 chronically infected 
with P. aeruginosa. A cough aerosol sampling system enabled fractioning of respiratory particles 
of different size, and culture of viable Gram negative non-fermentative bacteria. We collected 
cough aerosols during 5 minutes voluntary coughing and during a sputum induction procedure 
when tolerated. Standardized quantitative culture and genotyping techniques were used. 
 Results: P. aeruginosa was isolated in cough aerosols of 25 (89%) subjects of whom 22 
produced sputum samples. P. aeruginosa from sputum and paired cough aerosols were 
indistinguishable by molecular typing. In 4 cases the same genotype was isolated from ambient 
room air. Approximately 70% of viable aerosols collected during voluntary coughing were of 
particles ≤ 3.3 microns aerodynamic diameter. P. aeruginosa, Burkholderia cenocepacia 
Stenotrophomonas maltophilia and Achromobacter xylosoxidans were cultivated from respiratory 
particles in this size range. Positive room air samples were associated with high total counts in 
cough aerosols (P=0.003). The magnitude of cough aerosols were associated with higher FEV1 
(r=0.45, P=0.02) and higher quantitative sputum culture results (r=0.58, P=0.008).  
Conclusion:  During coughing, CF patients produce viable aerosols of P. aeruginosa and other 
Gram negative bacteria of respirable size range, suggesting the potential for airborne 
transmission.  
Key Words: cystic fibrosis; cough aerosol; airborne transmission; Pseudomonas aeruginosa 
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Introduction  
Pseudomonas aeruginosa is the most common bacterial pathogen in patients with cystic fibrosis 1 
(CF).[1] The prevalence of chronic P. aeruginosa increases with age, and is a major predictor of 2 
mortality and morbidity.[2] It is unclear to what extent cross-infection of P. aeruginosa between 3 
patients with CF occurs.[3, 4] Whilst siblings with CF can harbor the same P. aeruginosa strain,  4 
it was thought until recently that most patients had their own individual strain acquired from the 5 
environment.[5] With the advent of molecular typing methods there is now convincing evidence 6 
of clonal P. aeruginosa infection in patients attending some pediatric and adult CF centers.[6, 7]  7 
P. aeruginosa has been cultured from soap holders held at up to 40 cm from the mouth of 8 
coughing patients with CF, supporting large respiratory droplet spread.[8] The exact mechanisms 9 
involved in the spread of bacteria in CF clinics remain unclear.[6, 7] Two studies have isolated 10 
clonal P. aeruginosa during environmental air sampling up to ten metres from CF patients 11 
infected with clonal strains whilst performing physiotherapy and lung function testing suggesting 12 
the potential of person-to–person spread via the airborne route.[9, 10]  13 
 14 
Current guidelines for infection control for patients with CF recommend only contact and droplet 15 
precautions, i.e., focusing on hand hygiene and avoiding close contact between patients with CF, 16 
who are advised to maintain at least one meter distance from other patients.[11, 12]  It is possible 17 
that airborne transmission of P. aeruginosa, Burkholderia cepacia complex and other bacteria 18 
may occur in addition to other modes of transmission.[13] The relative contribution of the 19 
airborne route may be opportunistic in nature and occur in certain circumstances such as in 20 
enclosed spaces with favorable ambient temperature and humidity as may occur in hospital, clinic 21 
and congregate settings.  22 
 23 
 4
Particle size distribution of aerosols is a key determinant for both deposition in the respiratory 24 
tract and for the ability of particles to remain airborne.  To our knowledge, the particle size 25 
distribution of aerosols from patients with CF has never been reported. We hypothesized that 26 
during voluntary coughing and during sputum induction, subjects with CF produce viable 27 
bacterial aerosols that are respirable. To test this hypothesis, we modified a cough aerosol 28 
sampling system recently developed to measure cough-generated aerosols from patients with 29 
Mycobacterium tuberculosis.[14]  30 
 31 
Our primary aim was to determine the concentration and particle size distribution of cough 32 
aerosols containing culturable P. aeruginosa and other Gram-negative bacteria from children and 33 
adults with cystic fibrosis. We also sought to determine whether concentrations of cough aerosols 34 
detected were related to clinical parameters and clonality of P. aeruginosa strains.  35 
   36 
Methods  37 
Subjects:  Subjects with CF were recruited from both the inpatient and outpatient services at the 38 
Royal Children’s Hospital and The Prince Charles Hospital in Brisbane, Australia. Inclusion 39 
criteria were age older than 9 years, a confirmed diagnosis of CF and culture of Pseudomonas. 40 
aeruginosa or Burkholderia cepacia complex (Bcc) from sputum on at least one occasion within 41 
the previous 12 months. Exclusion criteria included known pregnancy, pneumothorax within the 42 
previous six months, history of cough syncope, or vomiting associated with coughing. After the 43 
first subject experienced recurrence of mild hemoptysis during the cough study, we excluded 44 
those with hemoptysis in the previous 7 days.  Subjects were excluded from hypertonic saline 45 
inhalation if there was a history of intolerance of hypertonic saline, presence of asthma 46 
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symptoms, or a forced expiratory volume in one second (FEV1) ≤ 40% predicted and no previous 47 
trials of hypertonic saline. Subjects were asked to withhold all nebulized therapy for 12 hours 48 
prior to testing. 49 
Ethics: The study was approved by the Ethics Committees of both CF centers and the University 50 
of Queensland and the Institutional Review Board of UMDNJ. Informed consent was obtained 51 
from all subjects and in addition from the parents or guardians of all young people under 18 years 52 
of age. 53 
Cough Aerosol Sampling System (CASS): The equipment used was a modification of that 54 
developed previously.[14] In brief, a subject coughs through a mouthpiece connected to afferent 55 
tubing into a chamber where upon a vacuum pump draws exhaled air and generated respiratory 56 
particles through one of two Anderson six stage impactors. Each stage has 400 holes of 57 
decreasing diameter through which appropriated sized aerosolized particles will penetrate and 58 
deposit on an agar plate. A ‘settle plate’ of the same agar was placed inside the chamber to 59 
capture larger droplets. Larger particles (droplets) would be expected to deposit in the afferent 60 
limb tubing, the settle plate and the walls of the chamber.  Additional details are provided in the 61 
online data supplement.  62 
 63 
 CASS Protocol: The Andersen impactors were loaded with agar plates at room temperature. The 64 
tubing from the vacuum pump was attached to the port for the first 6-stage impactor in the CASS.  65 
After the first session of coughing, the tubing was moved to the second sampler. All unused ports 66 
were occluded with plastic tape.    67 
 68 
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Subjects were instructed to cough into the CASS as frequently and as strongly as was 69 
comfortable for 5 minutes.  At the onset of coughing, the timer (set for 5 minutes) controlling the 70 
power to the vacuum pump was started. Cough strength was assessed as strong, moderate or 71 
weak and cough frequency was assessed quantitatively.  72 
 73 
If hypertonic saline could be tolerated, the first sampling was done during voluntary coughing, 74 
and the second five minute sample was collected during inhalation of 5mL of 4.5% saline 75 
delivered by a handheld ultrasonic nebulizer (Microneb Allersearch distributed by Becton 76 
Dickinson Pty. Ltd. North Ryde, Australia).  Subjects were pretreated with albuterol MDI (88 77 
mcg per puff), 4 puffs via spacer (Volumatic, Allen & Hanburys Ltd, UK). If hypertonic saline 78 
was not considered safe, sampling was done with the subject using tidal breathing for five 79 
minutes.  Sputum samples were collected if produced.    80 
 81 
Clinical Parameters: 82 
a. Pulmonary Function Testing: Forced expiratory volume in one second (FEV1) and forced 83 
vital capacity (FVC) were obtained according to standard guidelines prior to the cough study.[15] 84 
Respiratory muscle strength was assessed using maximum inspiratory (PImax) and expiratory 85 
(PEmax) pressures (Morgan Pmax) at the pediatric center and using a Micro Medical Respiratory 86 
Pressure Meter (Micro Medical LTD 2003) at the adult center. 87 
b.Other:  Age, gender, presence of current exacerbation of disease, height, weight and body mass 88 
index were recorded. 89 
 90 
Room Air Sampling and Air Exchange: Using a centrifugal air sampler, two samples were 91 
obtained prior to each cough aerosol study: one during the subjects’ performance of spirometry 92 
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and one during the cough aerosol study. The indoor air temperature and relative humidity were 93 
measured with a thermohygrometer (Rotronic HygroPalm 2, Rotronic Instrument Corp., 94 
Huntington, NY, USA) at the beginning of each study. Effective air exchange rates in the 95 
consultation rooms used for CASS testing and in the pulmonary function laboratory at the adult 96 
center were determined using carbon dioxide as a tracer gas. Further details are provided in the 97 
on line supplement. 98 
 99 
Microbiology:  100 
CASS aerosol samples and chamber settle plate: Cultures were performed using chocolate 101 
bacitracin (300 µg/mL) agar in aerobic conditions at 350C. After 48 and 72 hours incubation, a 102 
colony forming unit (CFU) count was performed on each plate including individual colonial 103 
P.aeruginosa morphotypes, and the combined total CFU count of P. aeruginosa and other Gram 104 
negative bacteria. Following presumptive screening (characteristic colonial appearance, presence 105 
of oxidase, and growth at 420C) each  P. aeruginosa isolate’s identity was confirmed by species-106 
specific oprL gene PCR.[16]. Other non-fermenting Gram negative bacteria detected throughout 107 
the study were identified using a combination of API 20NE (bioMerieux), amplified rDNA 108 
restriction analysis (ARDRA), and recA-based PCR analysis.[17, 18]  109 
 110 
Each Andersen sampler stage contains 400 holes and each colony forming unit is regarded as the 111 
result of an infectious particle within a specific size range impacting on the agar. Colony counts 112 
exceeding 400 have been interpreted in two ways: an accepted “positive-hole” correction model 113 
taking into account the probability of multiple hits through each hole and a conservative model of 114 
a maximum count of 400 only.[19, 20]  The total sum of P. aeruginosa or Bcc colonies counted 115 
(total count) in all the Andersen stages for 5 minutes of voluntary cough and for 5 minutes 116 
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hypertonic saline study or tidal breathing  was calculated , as was the sum of the colonies from 117 
stages 4, 5 and 6 (smaller than 3.3 microns termed ‘small aerosol fraction’).  118 
 119 
Sputa, afferent limb cultures and air samples: Standard quantitative culture methods were 120 
used.[21] For air samples and afferent limb cultures only Gram negative non fermentative 121 
bacteria were assessed. Isolates were identified as above with molecular strain typing of P. 122 
aeruginosa isolates. Further details are provided in the on line data supplement.  123 
 124 
Analysis 125 
Counts for individual components and totals across Andersen stages 1-6 (total) and for Andersen 126 
stages 4-6 (small fraction) were logarithmically transformed prior to analysis to correct for 127 
skewness. Means and 95 percent confidence limits were back-transformed from log to linear 128 
scales for presentation. The paired differences between counts during voluntary cough and each 129 
of hypertonic and tidal breathing studies were analysed by paired t-tests and mean differences 130 
were also back-transformed from log to linear scales to calculate the ratios of counts during 131 
voluntary cough and each of hypertonic and tidal breathing studies. Correlation coefficients were 132 
estimated between logarithmically transformed total counts and clinical and demographic factors 133 
where available for all subjects. Fisher’s exact test was used for the association between positive 134 
air samples and high total counts. All reported p values are two-sided. Linear regression was used 135 
to estimate the slope of the relationship between FEV1 and total count. All analyses were 136 
performed with SPSS software (version 15). 137 
 138 
 139 
 140 
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Results  141 
CASS Studies. 28 subjects (15 pediatric, 13 adult) were consecutively recruited and completed 142 
the five minutes of voluntary cough. Twenty subjects were administered nebulized hypertonic 143 
saline and seven subjects had measurements during tidal breathing. One subject performed 144 
voluntary cough only. Thirteen subjects were studied during a pulmonary exacerbation (Table 1).  145 
 146 
Sputum Microbiology. In the 12 months prior to study, 27 subjects had sputum that cultured 147 
positive for P. aeruginosa and one subject had cultured B. cenocepacia (Table 2). Of the 27 148 
patients with P. aeruginosa infection, all adults (n=12) and 14 children had chronic infection 149 
based on the Leeds criteria.[22] One child had recently cleared a new infection with P. 150 
aeruginosa following an eradication course of antibiotic therapy and cultured normal respiratory 151 
flora from a sputum sample collected on the day of testing.  The patient with B. cenocepacia had 152 
chronic infection based on the Leeds criteria (Table 2).[22] On the study day, 23 subjects 153 
provided expectorated sputum samples.  Of these, one subject grew B. cenocepacia as expected 154 
and P. aeruginosa was cultured in 21. Six subjects had Staphylococcus aureus cultured and two 155 
had Methicillin resistant S. aureus cultured. Other organisms cultured from sputum included 156 
alpha haemolytic Streptococci, Aspergillus species and yeasts.  Molecular strain typing 157 
demonstrated a common clone, corresponding to the previously described Australian Epidemic 158 
Strain-2 (AES-2) in 16 subjects (6 adults, 10 children) and 5 had unique strains (4 adults, 1 159 
child)(Table 2).[23]   160 
 161 
CASS Microbiology. Of the 28 subjects, 25 had cough aerosols that grew P. aeruginosa. One 162 
subject cultured P.aeruginosa from cough aerosols only with the hypertonic saline study and not 163 
from voluntary cough. One subject cultured B. cenocepacia from cough aerosols. Two subjects 164 
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had no Gram negative bacteria cultured from cough aerosols. In five subjects with cough aerosols 165 
with P. aeruginosa, additional Gram negative bacteria were co-cultured including 166 
Stenotrophomonas maltophilia in four and Achromobacter xylosoxidans in one (Table 2). Two of 167 
the subjects who co-cultured S. maltophilia did not produce sputum and sputum culture was 168 
negative for S. maltophilia for the other two. Three of the four subjects cultured S. maltophilia 169 
intermittently from sputum at other times. The subject with A. xylosoxidans in the cough aerosol 170 
culture did not culture the organism in the sputum sample on this occasion although the subject 171 
was known to be chronically infected with this organism which had been cultured repeatedly 172 
from previous sputum samples. 173 
 174 
Corrected total count of colony forming units obtained from generated aerosols varied widely 175 
among subjects and was log-normally distributed (voluntary cough range 0 - 13,485 CFU) (figure 176 
1). All subjects, but one, who cultured P. aeruginosa in sputum also cultured P. aeruginosa of 177 
identical genotype in the CASS cough aerosols. The total count from sputum correlated with total 178 
corrected count for voluntary cough from the aerosols (r=0.58 P=0.008).   Three out of seven 179 
subjects who had tidal breathing studies had positive CASS aerosol cultures, with P. aeruginosa 180 
cultured in low numbers (Total aerosol counts from tidal breathing 1, 5, 137 CFU).  181 
 182 
Settle Plate and Air Sampling Microbiology. The chamber settle plate and afferent limb 183 
equipment was not changed between the two components of the study for individual subjects 184 
with quantitative culture reflecting large droplet deposition for both components of the study 185 
combined. The mean total count for the settle plate was 6 CFU (95% confidence interval 3, 14). 186 
The mean total count for the afferent limb was 56 CFU/mL wash fluid (95% confidence interval 187 
10, 303 CFU/mL).  188 
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 189 
Air exchange rates ranged between 9.77 +/- 0.06 and 19.40 +/- 0.70 exchanges per hour (+/- 190 
calculated error) in the testing rooms.  101 air samples were collected before and during testing. 191 
Sixteen samples cultured unique strains of P. aeruginosa during testing of 14 patients. The 192 
unique strains isolated did not match any sputum or CASS isolates. Five air samples cultured 193 
AES2 strain during testing of four subjects with AES2 strain of P. aeruginosa. For these four 194 
subjects, sputum, cough aerosol and air samples all cultivated the same strain. Three of the AES2 195 
positive air samples were collected during pulmonary function testing, and two during 196 
background testing in the CASS study rooms.  Positive air samples were associated with high 197 
concentration in cough aerosols. If only subjects with AES2 were considered, 4 out of 5 subjects 198 
with total cough aerosol CFU counts above 1000 CFU had positive air samples and no subjects 199 
out of the 10 with lower total CFU counts had positive air samples (P=0.003). Temperature and 200 
humidity did not vary significantly between study sites or study days at each site (data not 201 
shown). 202 
 203 
CASS Microbiology: Voluntary cough, hypertonic cough and tidal breathing. The infective 204 
particle size distribution of cough aerosols of P. aeruginosa or B. cenocepacia during voluntary 205 
cough is shown in Figure 2. Using the corrected total counts 71.8% of particles (95% confidence 206 
interval 66.8, 76.8 %) containing culturable aerosol isolated from voluntary coughing were on 207 
Andersen stages 4, 5 and 6 of the Andersen samplers (small aerosol fraction ≤3.3 microns). The 208 
conservative model gave similar results with 69.9% (95% confidence interval 64.6, 75.4%) in the 209 
small aerosol fraction.  Mean total corrected counts were much lower during tidal breathing (2, 210 
95% confidence interval -0.5, 15) compared with voluntary cough (85, 95% confidence interval 211 
28, 238, P<0.001) or hypertonic saline (68, 95% confidence interval 21, 215). There was no 212 
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significant difference in total corrected counts between voluntary cough and hypertonic saline 213 
(P=0.12). The pattern of differences was unaffected by utilizing the conservative model (data not 214 
shown).   215 
 216 
CASS Microbiology: clinical correlates. FEV1 correlated with the total corrected count from the 217 
voluntary cough aerosol (r=0.45, P=0.019) (figure 3) and also with the corrected small aerosol 218 
fraction (r=0.45, P=0.018). Similarly, FEV1 correlated with the conservative total count (r=0.39, 219 
P=0.044) and conservative small aerosol fraction (r = 0.39, P= 0.047) during voluntary cough.  220 
There was no significant association between cough aerosol colony forming unit counts and any 221 
other clinical factor including gender, age, testing at pediatric or adult center, current 222 
exacerbation status, FVC, MIPs, MEPs, percentage predicted FEV1, presence of clonal P. 223 
aeruginosa, quality or actual number of coughs counted (data not shown). There was a trend for 224 
association of peak expiratory flow (r=0.36, P=0.079) and of body mass index (r=0.37, P=0.058) 225 
with total corrected count for voluntary cough.  226 
 227 
Discussion  228 
This is the first study to report the magnitude, variability, and particle size distribution of 229 
culturable aerosols of Gram negative bacteria produced by coughing in patients with CF. 230 
Although there is evidence of culturable Gram negative bacteria in the large droplets within the 231 
afferent tubing and settle plates in the cough chamber, a large proportion of culturable particles 232 
were found to be in a size range that is likely to deposit in the lower respiratory tract.  Genetically 233 
indistinguishable bacteria were identified in expectorated sputum and in the cough-generated 234 
aerosols, and in four experiments the same organisms were also isolated from the ambient room 235 
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air. This supports the assertion that the sources of the bacteria are the patients rather than the 236 
hospital or nearby environment. 237 
 238 
Aerosolisation of respiratory tract particles during cough and sneeze and even during tidal 239 
breathing, is a well recognized phenomenon associated with the spread of many infections 240 
including measles, influenza, and tuberculosis.[24-26]  The majority of respiratory pathogens 241 
have been thought to be spread by large droplets that settle within an approximate one meter 242 
range of an individual, providing a low risk of airborne infection. Infection control practices for 243 
most cystic fibrosis centers reflect recently published infection control guidelines suggesting that 244 
patients should maintain a distance of at least one meter to reduce the risk of cross infection.[12]. 245 
The risk of acquisition of infection from respiratory aerosols is complex and likely relates to the 246 
pathogen type, concentration of organism in aerosol, the susceptibility of exposed individuals and 247 
environment (air movement, relative humidity, temperature etc).  Limited studies have examined 248 
particle size distribution of respiratory aerosols and most have reported large droplet formation, 249 
predominantly particles having diameter greater than 8 microns.[27, 28]  More recently Papineni 250 
reported 85% of particles were under one micron and that coughing produced more aerosol 251 
particles than did breathing or talking.[29] The first published study to use a CASS examined 252 
patients with tuberculosis and like our study, found the majority of respiratory particles to be less 253 
than 3.3 microns.[14]  Our study demonstrates that CF patients produce culturable aerosols in a 254 
wide range of particle sizes, including both respiratory droplets and infectious droplet nuclei. We 255 
have shown this predominantly for clonal P. aeruginosa and, for a small number of patients, for 256 
other non-fermentative Gram negative organisms, including B. cenocepacia. We do not know the 257 
ideal site of deposition in the respiratory tract for P. aeruginosa to establish infection in people 258 
with CF and either large or small droplets or both may be important in the pathogenesis.  259 
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 260 
Until relatively recently, cross infection with P. aeruginosa was believed to be uncommon and 261 
limited to siblings with CF and cohorts attending the same residential CF camps.[30] The 262 
identification of genetically related P. aeruginosa strains in many CF centers in the UK, Europe 263 
and Australia has suggested cross-infection between patients.[23, 31] Clonal strains of P. 264 
aeruginosa contaminating the air close to patients with the same infection during physiotherapy 265 
or lung function testing have been reported.[9] Our results provide further evidence that cross-266 
infection may result from direct inhalation of aerosolized bacteria.  267 
 268 
This study demonstrates widely varying bacterial counts in cough aerosols with a log normal 269 
distribution. Such a distribution is consistent with descriptions of highly infectious patients as 270 
‘disseminators’ , e.g. in tuberculosis or ‘super-spreaders’, e.g. in Severe Acute Respiratory 271 
Syndrome.[32, 33]  Factors influencing the extent of isolation of Gram negative bacteria in cough 272 
aerosols are likely to be complex, including both host factors and bacterial factors such as 273 
enhanced survival in air.  Our data demonstrate that the concentration of bacteria in the sputum 274 
and the forced expiratory flow rates were related to cough aerosol concentration, with a trend for 275 
association with higher peak flow and higher body mass index. These data suggest that patients 276 
with milder lung disease, perhaps as a result of stronger cough, may have an increased risk of 277 
producing infectious aerosols. This warrants further investigation as the improvement in clinical 278 
outcomes in patients with CF may potentially increase the risk of spread of clonal strains of P. 279 
aeruginosa and other Gram negative bacteria.    280 
 281 
The only air samples that cultured P. aeruginosa which matched clinical samples from sputum or 282 
CASS samples were clonal AES2 strains. Given that patients who had positive air sample 283 
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associated also had high total aerosol counts, we were unable to determine if the density of 284 
infection on its own, or whether in addition the nature of the specific infection, contributed to 285 
positive air samples. The source of the P. aeruginosa air isolates that did not match any clinical 286 
samples is unknown and environmental sampling of surfaces was not undertaken. It is possible 287 
that environmental sources such as sinks may have been involved as hand washing occurred 288 
during testing.   The measured air exchange rates in the study rooms provide an important 289 
perspective as air sampling was performed for 12 minutes on each occasion and during this 290 
period 2-4 complete air exchanges occurred. Higher rates and density of positive air samples may 291 
be anticipated in less well ventilated rooms. 292 
 293 
Nebulized hypertonic saline is now a recognized therapy which improves mucociliary 294 
clearance.[34]  We sought to determine if hypertonic saline induced cough further enhanced the 295 
production of bacterial aerosols, however we noted similar results to those seen with voluntary 296 
coughing and much greater than seen during tidal breathing.  Therapies including physiotherapy, 297 
mucolytic agents and even nebulized antibiotics, which can induce coughing, are likely to result 298 
in similar cough induced aerosols as seen with voluntary cough. Although only seen in three of 299 
seven patients tested during tidal breathing, the presence of P. aeruginosa in the cough aerosols 300 
and in the small aerosol fraction from two patients warrants further study as any reassessment of 301 
infection control recommendations to incorporate the role of airborne transmission may not only 302 
apply to coughing patients. 303 
 304 
The significance of aerosol positive, sputum negative results for isolation in low numbers of S. 305 
maltophila (n=2) and A. xyloxidans (n=1) is uncertain but it is possible that separating respiratory 306 
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particles by size negates the obscuring of individual colony morphotypes by other flora which 307 
may occur with direct sputum culture. 308 
  309 
There are several limitations to this study. First, the study was not powered to examine the effects 310 
of many of the clinical variables, such as exacerbations or strain of P. aeruginosa on the 311 
production of cough aerosols. In particular there were few patients with unique strains of P. 312 
aeruginosa and none who produced high concentrations of cough aerosols. Therefore the 313 
association between specific strain and obtaining a positive air sample could not be determined. 314 
Second, the media in the Andersen plates was selective for Gram negative organisms, and thus it 315 
is not possible to generalize these results to patients with CF infected with Gram positive 316 
bacteria, mycobacteria, or fungi. Third, we did not perform reproducibility or efficiency studies 317 
of the CASS. Fourth, the studies of tidal breathing were a select group of patients who did not 318 
undertake hypertonic saline-induced cough studies and further work is required to evaluate the 319 
extent tidal breathing is associated with the generation of potentially infective particles. Finally, 320 
whilst this study provides evidence that patients with CF and Gram negative infection can 321 
produce potentially infectious cough aerosols, we cannot draw conclusions about transmission to 322 
susceptible individuals. A recent study examined the survival of P. aeruginosa in vitro and found 323 
bacterial survival, at least for a limited time period of less than 90 seconds, to be favoured by 324 
lower temperature and mucoid phenotype.[35].While providing further evidence that airborne 325 
transmission is plausible, transmission by this route is yet to be proven beyond doubt. 326 
  327 
In conclusion, this study demonstrates that patients with CF infected with P. aeruginosa can 328 
produce respirable infectious cough aerosols in a wide range of concentrations of a log normal 329 
distribution. We also detected other non-fermenting Gram negative bacteria, including B. 330 
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cenocepacia in the small aerosol fraction, suggesting airborne transmission of such organisms is 331 
biologically plausible. Further studies of potential airborne transmission of bacterial pathogens 332 
among CF patients are warranted to provide a scientific basis for infection control 333 
recommendations to prevent the spread of multidrug-resistant or clonal strains of P. aeruginosa 334 
and other Gram negative bacteria in this patient population.   335 
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Table 1. Subject Demographics and Baseline Clinical Factors 
 Paediatric Center 
n=15 
Adult Center 
n=13 
All 
n=28 
Age  in years median 
(range) 
13.5 (9.9-16.6) 25.8 (18.8-48.8) 16.4 (9.9-48.8) 
Gender (male/female) 8/7 9/4 17/11 
Current exacerbation 7 (47%) 6 (46%) 13 (46%) 
Body mass index 
 mean (SD) 
17.9 (2.5) 22.6 (3.7) 20.1 (3.9) 
Z score for weight mean 
(SD) 
-0.6 (0.9)   
Z score for height mean 
(SD) 
-0.5 (1.2)   
FEV1 % predicted  
mean (SD) 
67.0% (22.5 ) 52.4% (19.6) 60.2% (22.1) 
FVC % predicted 
Mean (SD) 
77.0% (19.6) 70.7% (15.4) 74.1% (17.7) 
Peak flow L/sec  
mean (SD)  
4.6 (2.2) 6.1 (1.9) 5.4 (2.2) 
MIPs cm H2O mean (SD)  82.8 (32.8)  
 
101.0 (30.1) 
 
91.1 (32.3) 
 
MEPs cmH2O mean (SD)  113.1 (42.9) 
 
103.6 (29.5) 
 
109.1 (37.4) 
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Table 2.  Microbiology of Sputum and CASS samples 
CASS study 
n=28 
Infection status prior 
to study 
Expectorated 
Sputum 
n= 23 
CASS study  
Voluntary Cough 
n=28 /hypertonic 
saline n=20 
Tidal study 
n=7 
P. aeruginosa 
not isolated 
Cleared P.aeruginosa 
n=1 
1 3 4 
P. aeruginosa 
isolated 
Chronic P.aeruginosa 
(n=12 adult,  
n=14 paediatric)  
21 25* 3 
P. aeruginosa (unique) 5 7 1 
P. aeruginosa (AES 2) 16 18 2 
B. cenocepacia 
isolated 
Chronic B. cenocepacia
n=1 
1 1 0 
* 5 subjects also cultured additional gram negative bacteria in cough aerosols ( 4 
Stenotrophomonas maltophilia and 1 Achromobacter xylosoxidans) 
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  Figure 1.   
Distribution of total corrected voluntary cough aerosols.  
B Subject with Burkholderia cenocepacia 
+ Positive ambient air samples isolated 
 
Figure 2.  
Particle size distribution of logarithmic corrected total cough aerosol counts in colony forming 
units with 95% confidence intervals during voluntary cough according to Anderson stage.   
 
Figure 3.   
Correlation of baseline forced expiratory volume in one second with logarithmic total corrected 
count from cough aerosols during voluntary cough. . 
+ Positive ambient air samples isolated 
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